USP17L21: A Potential Drug Target and Biomarker (G100287478)
USP17L21: A Potential Drug Target and Biomarker
USP17L21 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the USP family of proteins, which are involved in the regulation of cell growth and differentiation. USP17L21 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
The USP17L21 protein is composed of 21 amino acid residues and has a calculated molecular weight of 18.9 kDa. It is expressed in a variety of tissues, including the brain, heart, and kidneys, and is also found in the placenta and testes. USP17L21 is involved in the regulation of cell growth and differentiation, and has been shown to play a role in the development and progression of various diseases.
One of the key functions of USP17L21 is its role in the regulation of cell proliferation. Studies have shown that USP17L21 plays a negative role in the growth and survival of cancer cells, and that inhibition of its activity can lead to the regression of these cells. This suggests that USP17L21 may be an effective target for cancer therapies.
Another function of USP17L21 is its role in the regulation of cell death. Studies have shown that USP17L21 is involved in the production of cell death signals, and that its activity in this regard may be important for the regulation of cell life cycle. This suggests that USP17L21 may be an effective target for neurodegenerative diseases.
In addition to its role in cell proliferation and cell death, USP17L21 has also been shown to be involved in the regulation of inflammation. Studies have shown that USP17L21 is involved in the production of pro-inflammatory cytokines, and that its activity in this regard may be important for the development of autoimmune disorders.
The potential drug target and biomarker properties of USP17L21 make it an attractive target for further research. Further studies are needed to determine the exact mechanism of its activity and to determine its potential effectiveness as a drug. Additionally, research into the use of USP17L21 as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders, is also needed to determine its utility in these fields.
In conclusion, USP17L21 is a protein that is expressed in various tissues of the body and is involved in the regulation of cell growth and differentiation. Its potential as a drug target and biomarker for various diseases makes it an attractive target for further research. Further studies are needed to determine its exact mechanism of activity and its potential effectiveness as a drug, as well as its potential as a biomarker for various diseases.
Protein Name: Ubiquitin Specific Peptidase 17 Like Family Member 21
Functions: Deubiquitinating enzyme that removes conjugated ubiquitin from specific proteins to regulate different cellular processes that may include cell proliferation, progression through the cell cycle, apoptosis, cell migration, and the cellular response to viral infection
The "USP17L21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP17L21 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
USP17L24 | USP17L25 | USP17L26 | USP17L27 | USP17L29 | USP17L3 | USP17L5 | USP17L6P | USP17L7 | USP17L8 | USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14 | Vacuolar H+ ATPase | VAMP1 | VAMP2 | VAMP3 | VAMP4 | VAMP5 | VAMP7 | VAMP8 | VANGL1
